Peter Barber

Raymond James & Associates, Inc. (RJA) is a registered broker-dealer headquartered in St. Petersburg, Florida. The firm was founded in 1962 and is a subsidiary of Raymond James Financial, Inc. (NYSE: RJF), a diversified holding company. RJA offers a full array of capital markets services, strategic advice and planning for institutional investors.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Wachtell, Lipton, Rosen & Katz provides advisory and legal services. It specializes in mergers and acquisitions, strategic investments, takeovers and takeover defense, corporate and securities law, and corporate governance. The company was founded in 1965 and is headquartered in New York, NY.

Part of Fair Isaac Corp., Vertex Partners is a consulting firm based in Boston, MA. The company provides consulting services in various fields such as strategy/IT and recruiting. Vertex Partners combines the knowledge of many companies to create new ventures and supports initiatives related to innovation and new business creation. Luce, a recruitment firm, is a subsidiary of Vertex Partners. Accuchain, a company that modernizes HR recruitment software, is also a part of Vertex Partners. The company was founded by Paul J. Bascobert. Vertex Partners was acquired by Braun Consulting, Inc. on May 11, 1999.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH.

Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston.

Orbimed Private Investments VI LP seeks investment opportunities companies located in North America and Europe. The fund targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage, early stage, and later stage companies for both public and private companies with an investment size of $10 million to $75 million.

Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA.

Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA.

Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA.

Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.

Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer.

EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA.

Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then.